To precisely evaluate the ITPRIPL1 expression in NSCLC patients, we collected 75 groups of paired patient tissue samples (the tumor tissue and respective paracancerous tissue) and performed immunohistochemistry with our anti-ITPRIPL1 antibody. Here, ITPRIPL1 is linked to neoplasm.